July 24, 2025
Burning Rock Dx Laboratory Receives Accreditation from College of American Pathologists

GUANGZHOU, China, July 24, 2025—The Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to Burning Rock Dx Laboratory, Irvine, California based on results of a recent on-site inspection as part of the CAP's Accreditation Programs. Recognized for rigorous and robust standards, CAP accreditation elevates quality and mitigates risk, an important way that laboratories can contribute to improved patient outcomes.


The facility's director, Daniel C. Chen, MD, PhD, was advised of this global recognition and congratulated for the excellence of the services being provided. Burning Rock Dx Laboratory is one of more than 8,000 CAP-accredited facilities worldwide.


Burning Rock's Chief Executive Officer, Mr. Yusheng Han, upon learning of the laboratory's accreditation, said: “Achieving CAP accreditation reflects our unwavering commitment to the highest standards of laboratory quality and patient care. This recognition not only validates the dedication of our entire team in Irvine but also reinforces Burning Rock Dx’s mission to advance precision oncology through trusted and robust diagnostic solutions for patients worldwide.”


During the CAP accreditation process, designed to ensure the highest standard of care for all laboratory patients, inspectors examine the laboratory's records and quality control of procedures. CAP inspectors also examine laboratory staff qualifications, equipment, facilities, safety program and record, and overall management. These reviews help verify activities reflect the most recent best practices.


With over 23,000 laboratory participants, in addition to accreditation, the CAP offers proficiency testing/external quality assessment (PT/EQA) programs, quality improvement tools, and protocols and guidelines to ensure excellence in all areas across the laboratory. Built on a foundation of pathologist expertise, the College of American Pathologists (CAP) partners with laboratories worldwide to elevate the quality of laboratory medicine with best-in-class solutions designed to drive operational excellence, achieve diagnostic confidence, and ensure the best patient care.


About the College of American Pathologists

As the world's largest organization of board-certified pathologists and leading provider of laboratory accreditation and proficiency testing programs, the College of American Pathologists (CAP) serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide. For more information, visit the CAP Newsroom, CAP.org and yourpathologist.org to watch pathologists at work and see the stories of the patients who trust them with their care.


About Burning Rock

Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to guard life via science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of 1) NGS-based therapy selection testing for late-stage cancer patients, 2) Global pharmaceutical services on biomarker detection and companion diagnostics development, and 3) Early cancer detection which has moved beyond proof-of-concept R&D into the clinical validation stage. Burning Rock provides dedicated services to pharmaceutical partners, encompassing genomic data solutions, clinical trial solutions, precision patient recruitment, and companion diagnostics development and commercialization. Burning Rock has achieved two NMPA-approved IVD kits, four assays with CE marking, and a breakthrough device designation (BDD) received from both US FDA and China NMPA for multi-cancer detection blood test.

For more information about Burning Rock, please visit: https://www.brbiotech.com.
Learn More
June 01, 2022
Burning Rock Receives CE Mark Approval for Three NGS Tumor Kits
Learn More
March 15, 2022
Burning Rock Secures Second NGS Kit Approval from the NMPA
Learn More
November 17, 2021
Merck KGaA, Darmstadt, Germany and Burning Rock Collaborate on Liquid-biopsy Based CDx Development Using Burning Rock's OncoCompass™ Target
Learn More
August 03, 2021
Burning Rock and IMPACT Therapeutics Announce a Global Strategic Partnership for Companion Diagnostics Development
Learn More
April 29, 2021
Burning Rock and Abbisko Therapeutics Announce Strategic Partnership on Co-development of Companion Diagnostics for ABSK091
Learn More
June 29, 2020
Burning Rock and CStone Pharmaceuticals reached a strategic collaboration on the co-development of companion diagnostics for pralsetinib in China
Learn More
May 11, 2020
Burning Rock deepens cooperation with Illumina to promote development and standardization of NGS-based cancer therapy selection [in China]
Learn More
May 07, 2020
Burning Rock initiates the first prospective, multi-center pan-cancer early detection study in China
Learn More
1 2
Contact Our Experts
We would like to collect certain personal information about you through cookies and similar technologies in order to personalize the site for you, improve the performance of the site, and support our marketing efforts. By clicking “Accept All”, you confirm that we have your consent to collect and process your personal information in accordance with our Privacy Policy, which may include online targeted and social media advertising in some instances. You can by clicking “Reject All”, you can reject all cookies except for Strictly Necessary Cookies."